The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Priorities in Parkinson's disease research
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720 · cited 1×
“Among these symptoms, bradykinesia, resting tremors and rigidity are the core features of P”
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Second consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationMutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Self-citationA Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“Beyond dementia, major non-motor neuropsychiatric symptoms include depression, anxiety, apathy and psychosi”
BackgroundSelf-citationThe new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Self-citationKrack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationMemantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE
Schapira, A. H. V., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., & Marsden, C. D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92366-0 · Cited by 1,756
Self-citationGenome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Self-citationNon-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
Chaudhuri, K. R., & Schapira, A. H. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,738
Self-citationParkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Impulse Control Disorders in Parkinson Disease: A Cross-Sectional Study of 3090 Patients
Weintraub, D., Koester, J., Potenza, M. N., Siderowf, A. D., Stacy, M., Voon, V., Whetteckey, J., Wunderlich, G. R., & Lang, A. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.65 · Cited by 1,487
Self-citationDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Remy, P., Doder, M., Lees, A., Turjanski, N., & Brooks, D. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,040
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Self-citationEffect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
Olanow, C. W., Rascol, O., Hauser, R., Feigin, P. D., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809335 · Cited by 901
Self-citationSlower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Self-citationPramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Mapping of a gene for Parkinson's disease to chromosome 4q21-q23
Polymeropoulos, M. H., Higgins, J. J., Golbe, L. I., Johnson, W. G., Ide, S. E., Di Iorio, G., Sanges, G., Stenroos, E. S., Pho, L. T., Schaffer, A. A., et al. (1996) · Science · doi:10.1126/science.274.5290.1197 · Cited by 788
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
CENTRAL CERVICAL CORD SYNDROME AFTER HEADING A FOOTBALL
Scoppetta, C., & Vaccario, M. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92517-5 · Cited by 753
Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis
Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Burn, D., Barone, P., Pagonabarraga, J., Allcock, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39d0e · Cited by 748
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Self-citationFink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90173-9 · Cited by 650
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS)
Wenning, G. K., Tison, F., Seppi, K., Sampaio, C., Diem, A., Yekhlef, F., Ghorayeb, I., Ory, F., Galitzky, M., Scaravilli, T., et al. (2004) · Movement Disorders · doi:10.1002/mds.20255 · Cited by 606
Self-citationLoss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease
Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., Gasser, T., Wszolek, Z., Müller, T., Bornemann, A., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi215 · Cited by 568
Self-citationBarone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Self-citationNeuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Goldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 538
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El-Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 527
Molecular markers of early Parkinson's disease based on gene expression in blood
Scherzer, C. R., Eklund, A. C., Morse, L. J., Liao, Z., Locascio, J. J., Fefer, D., Schwarzschild, M. A., Schlossmacher, M. G., Hauser, M. A., Vance, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610204104 · Cited by 512
Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, A., & Wood, N. W. (2001) · The American Journal of Human Genetics · doi:10.1086/319522 · Cited by 493
Lo Bianco, C., Ridet, J.-L., Schneider, B. L., Déglon, N., & Aebischer, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152339799 · Cited by 482
Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson's disease
Ferraye, M. U., Debu, B., Fraix, V., Goetz, L., Ardouin, C., Yelnik, J., Henry-Lagrange, C., Seigneuret, E., Piallat, B., Krack, P., et al. (2010) · Brain · doi:10.1093/brain/awp229 · Cited by 477
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Self-citationAarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70146-2 · Cited by 459
The metabolic topography of parkinsonism
Eidelberg, D., Moeller, J. R., Dhawan, V., Spetsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D., Przedborski, S., et al. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.99 · Cited by 455
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease
Vaillancourt, D. E., Spraker, M. B., Prodoehl, J., Abraham, I., Corcos, D. M., Zhou, X. J., Comella, C. L., & Little, D. M. (2009) · Neurology · doi:10.1212/01.wnl.0000340982.01727.6e · Cited by 438
Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., Tolosa, E., Kutzelnigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., & Jones, R. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70194-0 · Cited by 436
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Nyholm, D., Nilsson Remahl, A. I. M., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R., Aquilonius, S. M., & Askmark, H. (2005) · Neurology · doi:10.1212/01.wnl.0000149637.70961.4c · Cited by 432
Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N., Villemagne, V. L., O'Keefe, G., Nagren, K., Chaudhury, K. R., et al. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127878 · Cited by 431
Stiasny-Kolster, K. (2004) · Brain · doi:10.1093/brain/awh322 · Cited by 430
Unilateral pedunculopontine stimulation improves falls in Parkinson's disease
Moro, E., Hamani, C., Poon, Y.-Y., Al-Khairallah, T., Dostrovsky, J. O., Hutchison, W. D., & Lozano, A. M. (2010) · Brain · doi:10.1093/brain/awp261 · Cited by 427
Self-citationFDG PET in the differential diagnosis of parkinsonian disorders
Eckert, T., Barnes, A., Dhawan, V., Frucht, S., Gordon, M. F., Feigin, A. S., & Eidelberg, D. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.03.012 · Cited by 419
A controlled trial of antidepressants in patients with Parkinson disease and depression
Menza, M., Dobkin, R. D., Marin, H., Mark, M. H., Gara, M., Buyske, S., Bienfait, K., & Dicke, A. (2009) · Neurology · doi:10.1212/01.wnl.0000336340.89821.b3 · Cited by 414
Relationships between age and late progression of Parkinson's disease: a clinico-pathological study
Kempster, P. A., O'Sullivan, S. S., Holton, J. L., Revesz, T., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq059 · Cited by 410
Kirik, D., Annett, L. E., Burger, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536383100 · Cited by 403
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature
Péran, P., Cherubini, A., Assogna, F., Piras, F., Quattrocchi, C., Peppe, A., Celsis, P., Rascol, O., Démonet, J.-F., Stefani, A., et al. (2010) · Brain · doi:10.1093/brain/awq212 · Cited by 399
Self-citationPARK7, a Novel Locus for Autosomal Recessive Early-Onset Parkinsonism, on Chromosome 1p36
van Duijn, C. M., Dekker, M. C. J., Bonifati, V., Galjaard, R. J., Houwing-Duistermaat, J. J., Snijders, P. J. L. M., Testers, L., Breedveld, G. J., Horstink, M., Sandkuijl, L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/322996 · Cited by 379
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., & Clark, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 378
Matsumine, H., Saito, M., Shimoda‐Matsubayashi, S., Tanaka, H., Ishikawa, A., Nakagawa-Hattori, Y., Yokochi, M., Kobayashi, T., Igarashi, S., Takano, H., et al. (1997) · Europe PMC (PubMed Central) · Cited by 377
Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376
Self-citationThe role of radiotracer imaging in Parkinson disease
Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 374
Multiple system atrophy: an update
Stefanova, N., Bücke, P., Duerr, S., & Wenning, G. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70288-1 · Cited by 373
Transcranial sonography in movement disorders
Berg, D., Godau, J., & Walter, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70239-4 · Cited by 372
LeWitt, P. A., Guttman, M., Tetrud, J. W., Tuite, P. J., Mori, A., Chaikin, P., Sussman, N. M., & 6002‐US‐005 Study Group (2008) · Annals of Neurology · doi:10.1002/ana.21315 · Cited by 356
Midbrain iron content in early Parkinson disease: A potential biomarker of disease status
Martin, W. R. W., Wieler, M., & Gee, M. (2008) · Neurology · doi:10.1212/01.wnl.0000286384.31050.b5 · Cited by 354
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2009) · Brain · doi:10.1093/brain/awn291 · Cited by 347
Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70287-x · Cited by 335
Self-citationPollak, P. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029868 · Cited by 333
Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease
Lidstone, S. C., Schulzer, M., Dinelle, K., Mak, E., Sossi, V., Ruth, T. J., de la Fuente-Fernández, R., Phillips, A. G., & Stoessl, A. J. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.88 · Cited by 323
When Does Parkinson Disease Start?
Savica, R., Rocca, W. A., & Ahlskog, J. E. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.135 · Cited by 312
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Self-citationMeltzer, H. Y., Mills, R., Revell, S., Williams, H., Johnson, A., Bahr, D., & Friedman, J. H. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.176 · Cited by 292
SNCA variants are associated with increased risk for multiple system atrophy
Scholz, S. W., Houlden, H., Schulte, C., Sharma, M., Li, A., Berg, D., Melchers, A., Paudel, R., Gibbs, J. R., Simon‐Sanchez, J., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21685 · Cited by 281
Self-citationDevos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L. (2008) · Movement Disorders · doi:10.1002/mds.21966 · Cited by 274
Zesiewicz, T. A., Sullivan, K. L., Arnulf, I., Chaudhuri, K. R., Morgan, J. C., Gronseth, G. S., Miyasaki, J., Iverson, D. J., & Weiner, W. J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d55f24 · Cited by 273
Goetz, C. G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C. W., Rascol, O., & Russ, H. (2007) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Self-citationGoetz, C. G., Wuu, J., McDermott, M. P., Adler, C. H., Fahn, S., Freed, C. R., Hauser, R. A., Olanow, W. C., Shoulson, I., Tandon, P. K., et al. (2008) · Movement Disorders · doi:10.1002/mds.21894 · Cited by 253
Self-citationThe Unified Dyskinesia Rating Scale: Presentation and clinimetric profile
Goetz, C. G., Nutt, J. G., & Stebbins, G. T. (2008) · Movement Disorders · doi:10.1002/mds.22341 · Cited by 251
Self-citationZonisamide improves motor function in Parkinson disease: A randomized, double-blind study
Murata, M., Hasegawa, K., Kanazawa, I., & The Japan Zonisamide on PD Study Group (2007) · Neurology · doi:10.1212/01.wnl.0000250236.75053.16 · Cited by 238
Pathological gambling in Parkinson disease is reduced by amantadine
Thomas, A., Bonanni, L., Gambi, F., Di Iorio, A., & Onofrj, M. (2010) · Annals of Neurology · doi:10.1002/ana.22029 · Cited by 235
Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease
Ascherio, A., Chen, H., Schwarzschild, M. A., Zhang, S. M., Colditz, G. A., & Speizer, F. E. (2003) · Neurology · doi:10.1212/01.wnl.0000046523.05125.87 · Cited by 234
Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures
Politis, M., Wu, K., Loane, C., Turkheimer, F. E., Molloy, S., Brooks, D. J., & Piccini, P. (2010) · Neurology · doi:10.1212/wnl.0b013e3181feb2ab · Cited by 224
Self-citationMandel, S. A., Amit, T., Weinreb, O., Reznichenko, L., & Youdim, M. B. H. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00060.x · Cited by 221
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
Hauser, R. A., Shulman, L. M., Trugman, J. M., Roberts, J. W., Mori, A., Ballerini, R., & Sussman, N. M. (2008) · Movement Disorders · doi:10.1002/mds.22095 · Cited by 207
Molecular and clinical prodrome of Parkinson disease: implications for treatment
Schapira, A. H. V., & Tolosa, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.52 · Cited by 202
Self-citationPéchevis, M., Clarke, C. E., Vieregge, P., Khoshnood, B., Deschaseaux‐Voinet, C., Berdeaux, G., Ziegler, M., & on behalf of the Trial Study Group (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01096.x · Cited by 196
Hauser, R. A., Cantillon, M., Pourcher, E., Micheli, F., Mok, V., Onofrj, M., Huyck, S., & Wolski, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70012-6 · Cited by 194
LRRK2 Gly2019Ser penetrance in Arab–Berber patients from Tunisia: a case-control genetic study
Hulihan, M. M., Ishihara-Paul, L., Kachergus, J., Warren, L., Amouri, R., Elango, R., Prinjha, R. K., Upmanyu, R., Kefi, M., Zouari, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70116-9 · Cited by 190
Clinical efficacy of istradefylline (KW‐6002) in Parkinson's disease: A randomized, controlled study
Mizuno, Y., Hasegawa, K., Kondo, T., Kuno, S., Yamamoto, M., & The Japanese Istradefylline Study Group (2010) · Movement Disorders · doi:10.1002/mds.23107 · Cited by 188
Dodel, R., Spottke, A., Gerhard, A., Reuss, A., Reinecker, S., Schimke, N., Trenkwalder, C., Sixel‐Döring, F., Herting, B., Kamm, C., et al. (2010) · Movement Disorders · doi:10.1002/mds.22732 · Cited by 187
Self-citationDopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
Stacy, M., Silver, D., Mendis, T., Sutton, J., Mori, A., Chaikin, P., & Sussman, N. M. (2008) · Neurology · doi:10.1212/01.wnl.0000313834.22171.17 · Cited by 182
What causes mental dysfunction in Parkinson's disease?
Emre, M. (2003) · Movement Disorders · doi:10.1002/mds.10565 · Cited by 182
A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results
(2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181342f32 · Cited by 174
Bjorness, T., & Greene, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909789152182 · Cited by 172
Bartus, R. T., Herzog, C. D., Chu, Y., Wilson, A., Brown, L., Siffert, J., Johnson, E. M., Olanow, C. W., Mufson, E. J., & Kordower, J. H. (2011) · Movement Disorders · doi:10.1002/mds.23442 · Cited by 171
Olanow, C. W., Hauser, R. A., Jankovic, J., Langston, W., Lang, A., Poewe, W., Tolosa, E., Stocchi, F., Melamed, E., Eyal, E., et al. (2008) · Movement Disorders · doi:10.1002/mds.22218 · Cited by 167
Self-citationThe Parkinson Disease Gene LRRK2: Evolutionary and Structural Insights
Marín, I. (2006) · Molecular Biology and Evolution · doi:10.1093/molbev/msl114 · Cited by 165
Prediger, R. D. S. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091459 · Cited by 160
Dusonchet, J., Kochubey, O., Stafa, K., Young, S., Zufferey, R., Moore, D. J., Schneider, B. L., & Aebischer, P. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5092-10.2011 · Cited by 160
Classification of fluctuations in patients with Parkinson's disease
Quinn, N. P. (1998) · Neurology · doi:10.1212/wnl.51.2_suppl_2.s25 · Cited by 158
Devos, D., Krystkowiak, P. C., Clement, F., Dujardin, K., Cottencin, O., Waucquier, N., Ajebbar, K., Thielemans, B., Kroumova, M., Duhamel, A., et al. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100016 · Cited by 153
Marsh, L., Biglan, K., Gerstenhaber, M., & Williams, J. R. (2008) · Movement Disorders · doi:10.1002/mds.22307 · Cited by 144
Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism
Nutt, J. G., Gunzler, S. A., Kirchhoff, T., Hogarth, P., Weaver, J. L., Krams, M., Jamerson, B., Menniti, F. S., & Landen, J. W. (2008) · Movement Disorders · doi:10.1002/mds.22169 · Cited by 133
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
Placebo influences on dyskinesia in Parkinson's disease
Goetz, C. G., LASKA, E. M., Hicking, C., Damier, P., Müller, T. H., Nutt, J. G., Olanow, C. W., Rascol, O., & Russ, H. (2008) · Movement Disorders · doi:10.1002/mds.21897 · Cited by 123
Self-citationProgression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study
Nandhagopal, R., Mak, E., Schulzer, M., McKenzie, J., McCormick, S., Sossi, V., Ruth, T. J., Strongosky, A. J., Farrer, M. J., Wszołek, Z. K., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000335973.66333.58 · Cited by 119
Non-dopaminergic treatments in development for Parkinson's disease
Fox, S. H., Brotchie, J. M., & Lang, A. E. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70214-x · Cited by 116
Colosimo, C., Martínez‐Martín, P., Fabbrini, G., et al. (2010) · Movement Disorders · doi:10.1002/mds.23072 · Cited by 115
Kikuchi, A., Takeda, A., Okamura, N., Tashiro, M., Hasegawa, T., Furumoto, S., Kobayashi, M., Sugeno, N., Baba, T., Miki, Y., et al. (2010) · Brain · doi:10.1093/brain/awq091 · Cited by 113
Rasagiline, Parkinson neuroprotection, and delayed-start trials
Ahlskog, J. E., & Uitti, R. J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d7d8e2 · Cited by 105
Animal models of multiple system atrophy
Stefanova, N., & Wenning, G. K. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0266-6 · Cited by 94
Meissner, W. G., Hill, M. P., Tison, F., Gross, C. E., & Bézard, E. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.003 · Cited by 88
Self-citationThalamic single‐unit and local field potential activity in Tourette syndrome
Marceglia, S. R. F., Servello, D., Foffani, G., Porta, M., Sassi, M., Mrakic‐Sposta, S., Rosa, M., Barbieri, S., & Priori, A. (2010) · Movement Disorders · doi:10.1002/mds.22982 · Cited by 87
Eggert, K. M., Squillacote, D., Barone, P., Dodel, R. C., Katzenschlager, R., Emre, M., Lees, A. J., Rascol, O., Poewe, W. H., TOLOSA, E. S., et al. (2010) · Movement Disorders · doi:10.1002/mds.22974 · Cited by 76
Self-citationHauser, R. A., & Holford, N. H. G. (2002) · Movement Disorders · doi:10.1002/mds.10226 · Cited by 74
Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach
van Dijk, K. D., Teunissen, C. E., Drukarch, B., Jiménez, C. R., Groenewegen, H. J., Berendse, H. W., & van de Berg, W. D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.04.020 · Cited by 73
Animal models of multiple system atrophy
Stefanova, N., Tison, F., Reindl, M., Poewe, W. H., & Wenning, G. K. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.07.002 · Cited by 71
Self-citationMorrish, P. (2003) · Movement Disorders · doi:10.1002/mds.10581 · Cited by 69
Holmberg, B., Johansson, J., Poewe, W. H., Wenning, G. K., Quinn, N. P., Mathias, C. J., TOLOSA, E. S., Cardozo, A., Dizdar, N., Rascol, O., et al. (2007) · Movement Disorders · doi:10.1002/mds.21501 · Cited by 69
Self-citationMeasuring health‐related quality of life in MSA: The MSA‐QoL
Schrag, A. E., Selai, C. E., Mathias, C. J., Low, P. A., Hobart, J. C., Brady, N., & Quinn, N. P. (2007) · Movement Disorders · doi:10.1002/mds.21649 · Cited by 66
“Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design
Rascol, O. (2009) · Neurology · doi:10.1212/wnl.0b013e318199049e · Cited by 60
Self-citationSafinamide in the treatment of Parkinson's disease
Schapira, A. H. V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.511612 · Cited by 48
Self-citationHauptmann, C., Popovych, O. V., & Tass, P. A. (2007) · Expert Review of Medical Devices · doi:10.1586/17434440.4.5.633 · Cited by 41
Quantifying the impact of dyskinesias in PD
Katzenschlager, R., Schrag, A. E., Evans, A. H., Manson, A. J., Carroll, C., Ottaviani, D., Lees, A. J., & Hobart, J. (2007) · Neurology · doi:10.1212/01.wnl.0000266669.18308.af · Cited by 40
Caffeine and Progression of Parkinson Disease
Simon, D. K., Swearingen, C. J., Hauser, R. A., Trugman, J. M., Aminoff, M. J., Singer, C., Truong, D. D., & Tilley, B. C. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31815a3f03 · Cited by 38
Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
Bronzova, J., Sampaio, C., Hauser, R. A., Lang, A. E., Rascol, O., Theeuwes, A. G. M., Witte, S., van Scharrenburg, G., & on behalf of the Bruegel Study Group (2010) · Movement Disorders · doi:10.1002/mds.22948 · Cited by 37
Self-citationEtiopathogenesis and treatment of Parkinson's disease.
Gallagher, D. A., & Schapira, A. H. V. (2009) · PubMed · Cited by 29
Self-citationInterpreting the results of Parkinson's disease clinical trials: Time for a change
Holford, N. H. G., & Nutt, J. G. (2011) · Movement Disorders · doi:10.1002/mds.23555 · Cited by 28
Cited by
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Chromone: A Valid Scaffold in Medicinal Chemistry
Gaspar, A., Matos, M. J., Garrido, J., Uriarte, E., & Borges, F. (2014) · Chemical Reviews · doi:10.1021/cr400265z · Cited by 760
Dehay, B., Bourdenx, M., Gorry, P., Przedborski, S., Vila, M., Hunot, S., Singleton, A., Olanow, C. W., Merchant, K. M., Bezard, E., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00006-x · Cited by 529
Self-citationBiałkowska, K., Komorowski, P., Bryszewska, M., & Miłowska, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176225 · Cited by 382
A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice
Chesselet, M.-F., Richter, F., Zhu, C., Magen, I., Watson, M. B., & Subramaniam, S. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0104-2 · Cited by 346
Metadata
- Authors
- Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., Weiner, D. M., Tison, F., & Bezard, E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04-29
- Volume
- 10
- Issue
- 5
- Pages
- 377-393
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2002917813
- Cited by
- 436
- References
- 140
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.